

# Gene therapy – promises, problems and prospects

Inder M. Verma and Nikunj Somia

**In principle, gene therapy is simple: putting corrective genetic material into cells alleviates the symptoms of disease. In practice, considerable obstacles have emerged. But, thanks to better delivery systems, there is hope that the technique will succeed.**

In 1990, the first clinical trials for gene-therapy approaches to combat disease were carried out. Conceptually, the technique involves identifying appropriate DNA sequences and cell types, then developing suitable ways in which to get enough of the DNA into these cells. With efficient delivery, the therapeutic prospects range from tackling genetic diseases and slowing the progression of tumours, to fighting viral infections and stopping neurodegenerative diseases. But the problems — such as the lack of efficient delivery systems, lack of sustained expression, and host immune reactions — remain formidable challenges.

Although more than 200 clinical trials are currently underway worldwide, with hundreds of patients enrolled, there is still no single outcome that we can point to as a success story. To explore why this is the case, we will use our own experience and other examples to look at the many technical, logistical and, in some cases, conceptual hurdles that need to be overcome before gene therapy becomes routine practice in medicine.

At present, gene therapy is being contemplated only on somatic (essentially, non-reproductive) cells. Although many somatic tissues can receive therapeutic DNA, the choice of cell usually depends on the nature of the disease. Sometimes a clear definition of the target cell is needed. For example, the gene that is defective in cystic fibrosis has been identified, and clinical trials to deliver DNA as an aerosol into the lung have already begun<sup>1</sup>. Although cystic fibrosis is manifest in this organ, it is still not clear that delivery of a correcting gene by this method will reach the right type of cell. On the other hand, to correct blood-clotting disorders such as haemophilia, all that is needed is a therapeutic level of clotting protein in the plasma<sup>2</sup>. This protein may be supplied by muscle or liver cells, fibroblasts, or even blood cells<sup>3–5</sup>. The choice of tissue in which to express the therapeutic protein will also ultimately depend on considerations such as the efficiency of gene delivery, protein modifications, immunological


status, accessibility and economics.

We also need to consider how much of the therapeutic protein should be delivered. In haemophilia B, which is caused by a deficiency of a blood-clotting protein called factor IX, giving patients just 5% of the normal circulating levels of this protein can substantially improve their quality of life<sup>2</sup>. Most people have about 5 µg of factor IX per millilitre of plasma, produced by the 10<sup>13</sup> cells that make up the liver. So we need to deliver a correcting gene to 5 × 10<sup>11</sup> cells — that is, 5% of liver cells. Alternatively, fewer liver cells would need to be modified if more factor IX could be produced per cell, without being deleterious. In the brain, however, gene transfer to just a few hundred cells

could considerably benefit patients with neurological disease. And finally, we can consider the transfer of genes to a handful of stem (or progenitor) cells, which grow and divide to generate millions of progeny. The range in the number of cells that this technology has to cover is vast.

The Achilles heel of gene therapy is gene delivery, and this is the aspect that we will concentrate on here. Thus far, the problem has been an inability to deliver genes efficiently and to obtain sustained expression. There are two categories of delivery vehicle ('vector'). The first comprises the non-viral vectors, ranging from direct injection of DNA to mixing the DNA with polylysine or cationic lipids that allow the gene to cross the cell membrane. Most of these approaches suffer from poor efficiency of delivery and transient expression of the gene<sup>6</sup>. Although there are reagents that increase the efficiency of delivery, transient expression of the transgene is a conceptual hurdle that needs to be addressed.

Most of the current gene-therapy approaches make use of the second category — viral vectors. Importantly, the viruses used have all been disabled of any pathogenic effects. The use of viruses is a powerful technique, because many of them have evolved a specific machinery to deliver DNA to cells. However, humans have an immune system to fight off the virus, and our attempts to deliver genes in viral vectors have been confronted by these host responses. ▶



**Figure 1** To create the retroviral vectors that are used in gene therapy, the life-cycles of their naturally occurring counterparts are exploited. a, The transgene (in this case, the gene for factor IX) in a vector backbone is put into a packaging cell, which expresses the genes that are required for viral integration (*gag*, *pol* and *env*). b, The transgene is incorporated into the nucleus, where it is transcribed to make vector RNA. This is then packaged into the retroviral vector, which is shed from the packaging cell. c, The vector is delivered to the target cell by infection. The membrane of the viral vector fuses with the target cell, allowing the vector RNA to enter. d, The vially encoded enzyme reverse transcriptase converts the vector RNA into an RNA–DNA hybrid, and then into double-stranded DNA. e, The vector DNA is integrated into the host genome, then the host-cell machinery will transcribe and translate it to make RNA and, in this case, factor IX protein. LTR, long terminal repeat; ψ, packaging sequence.

**Retroviral vectors**

Retroviruses are a group of viruses whose RNA genome is converted to DNA in the infected cell. The genome comprises three genes termed *gag*, *pol* and *env*, which are flanked by elements called long terminal repeats (LTRs). These are required for integration into the host genome, and they define the beginning and end of the viral genome. The LTRs also serve as enhancer–promoter sequences — that is, they control expression of the viral genes. The final element of the genome, called the packaging sequence ( $\psi$ ), allows the viral RNA to be distinguished from other RNAs in the cell (Fig. 1)<sup>7</sup>.

By manipulating the viral genome, viral genes can be replaced with transgenes — such as the gene for factor IX (Table 1). Transcription of the transgene may be under the control of viral LTRs or, alternatively, enhancer–promoter elements can be engineered in with the transgene. The chimaeric genome is then introduced into a packaging cell, which produces all of the viral proteins (such as the products of the *gag*, *pol* and *env* genes), but these have been separated from the LTRs and the packaging sequence. So, only the chimaeric viral genomes are assembled to generate a retroviral vector. The culture medium in which these packaging cells have been grown is then applied to the target cells, resulting in transfer of the transgene. Typically, a million target cells on a culture dish can be infected with one millilitre of the viral soup.

A critical limitation of retroviral vectors is their inability to infect non-dividing cells<sup>8</sup>, such as those that make up muscle, brain, lung and liver tissue. So, when possible, the cells from the target tissue are removed,

grown *in vitro*, and infected with the recombinant retroviral vector. The target cells producing the foreign protein are then transplanted back into the animal. This procedure has been termed ‘*ex vivo* gene therapy’ and our group has used it to infect mouse primary fibroblasts or myoblasts (connective-tissue and muscle precursors, respectively) with retroviral vectors producing the factor IX protein. But within five to seven days of transplanting the infected cells back into mice, expression of factor IX is shut off<sup>3,5,9</sup>. This transcriptional shut-off has even been observed in mice lacking a functional immune system (nude mice), and it cannot be due to cell loss or gene deletion<sup>5</sup> because the transplanted cells can be recovered.

What is the mechanism of this unexpected but intriguing problem? We do not yet know, but the exceptions may provide some clues. To obtain sustained expression in mouse muscle following the transplantation of infected myoblasts, we used the muscle creatine kinase enhancer–promoter to control transcription of the transgene. Unfortunately, this is a weak promoter, and only low levels of protein were produced. So, we generated a chimaeric vector in which the muscle creatine kinase enhancer was linked to a strong promoter from cytomegalovirus. Using this vector, sustained and high levels of factor IX were expressed when the infected myoblasts were transplanted back into mice. Remarkably, these expression levels remained unchanged for more than two years (the life of the animal). So we can override the ‘off switch’ and achieve higher levels of expression by using an appropriate enhancer–promoter combination. But the search for such combinations is a case

of trial and error for a given type of cell.

Another formidable challenge to the *ex vivo* approach is the efficiency of transplantation of the infected cells. Attempts to repeat the long-term myoblast transplantation in haemophilic dogs led to only short-term expression, because the infected dog myoblasts could not fuse with the muscle fibres. So perhaps successful animal models will prove inadequate when the same protocols are extended to humans. Moreover, these models are based on inbred animals — the outbred human population, with individual variation, will add yet another degree of complexity. The haematopoietic (blood-producing) system may offer an advantage for *ex vivo* gene therapy because resting stem cells can be stimulated to divide *in vitro* using growth factors and the transplantation technology is well established. But there is still a lack of good enhancer–promoter combinations that allow sustained production of high levels of protein in these cells.

Another problem is the possibility of random integration of vector DNA into the host chromosome. This could lead to activation of oncogenes or inactivation of tumour-suppressor genes. Although the theoretical probability of such an event is quite low, it is of some concern (see section on clinical trials).

**Lentiviral vectors**

Lentiviruses also belong to the retrovirus family, but they can infect both dividing and non-dividing cells<sup>10</sup>. The best-known lentivirus is the human immunodeficiency virus (HIV), which has been disabled and developed as a vector for *in vivo* gene delivery. Like the simple retroviruses, HIV has the three *gag*, *pol* and *env* genes, but it also carries genes for six accessory proteins termed *tat*, *rev*, *vpr*, *vpu*, *nef* and *vif*<sup>11</sup>.

Using the retrovirus vectors as a model, lentivirus vectors have been made, with the transgene enclosed between the LTRs and a packaging sequence<sup>12</sup>. Some of the accessory proteins can be eliminated without affecting production of the vector or efficiency of infection. The *env* gene product would restrict HIV-based vectors to infecting only cells that express a protein called CD4<sup>1</sup> so, in the vectors, this gene is substituted with *env* sequences from other RNA viruses that have a broader infection spectrum (such as glycoprotein from the vesicular stomatitis virus). These vectors can be produced — albeit on a small scale at the moment — at concentrations of >10<sup>9</sup> virus particles per ml (ref.12).

When lentivirus vectors are injected into rodent brain, liver, muscle, eye or pancreatic-islet cells, they give sustained expression for over six months — the longest time tested so far<sup>13,14</sup>. Unlike the prototypical retroviral vectors, the expression is not subject to ‘shut off’. Little is known about the possible immune problems associated with lentiviral vectors, but injection of 10<sup>7</sup> infectious units

Table 1 **Candidate diseases for gene therapy**

Disease	Defect	Incidence	Target cells
<b>Genetic</b>			
Severe combined immunodeficiency (SCID/ADA)	Adenosine deaminase (ADA) in ~25% of SCID patients	Rare	Bone-marrow cells or T lymphocytes
Haemophilia	A Factor VIII deficiency	1:10,000 males	Liver, muscle, fibroblasts or bone-marrow cells
	B Factor IX deficiency	1:30,000 males	
Familial hypercholesterolaemia	Deficiency of low-density lipoprotein (LDL) receptor	1:1 million	Liver
Cystic fibrosis	Faulty transport of salt in lung epithelium. Loss of <i>CFTR</i> gene	1:3,000 Caucasians	Airways in the lungs
Haemoglobinopathies: thalassaemias/sickle-cell anaemia	Structural defects in $\alpha$ - or $\beta$ -globin gene	1:600 in certain ethnic groups	Bone-marrow cells, giving rise to red blood cells
Gaucher's disease	Defect in the enzyme glucocerebrosidase	1:450 in Ashkenazi Jews	Bone-marrow cells, macrophages
$\alpha_1$ -antitrypsin deficiency: inherited emphysema	Lack of $\alpha_1$ -antitrypsin	1:3,500	Lung or liver cells
<b>Acquired</b>			
Cancer	Many causes, including genetic and environmental	1 million/year in USA	Variety of cancer-cell types; liver, brain, pancreas, breast, kidney
Neurological diseases	Parkinson's, Alzheimer's, spinal-cord injury	1 million Parkinson's and 4 million Alzheimer's patients in USA	Direct injection in the brain, neurons, glial cells, Schwann cells
Cardiovascular	Restinosis, arteriosclerosis	13 million in USA	Arteries, vascular endothelial cells
Infectious diseases	AIDS, hepatitis B	Increasing numbers	T cells, liver, macrophages

does not elicit the cellular immune response at the site of injection. Furthermore, there seems to be no potent antibody response. So, at present, lentiviral vectors seem to offer an excellent opportunity for *in vivo* gene delivery with sustained expression.

### Adenoviral vectors

The adenoviruses are a family of DNA viruses that can infect both dividing and non-dividing cells, causing benign respiratory-tract infections in humans<sup>11</sup>. Their genomes contain over a dozen genes, and they do not usually integrate into the host DNA. Instead, they are replicated as episomal (extrachromosomal) elements in the nucleus of the host cell. Replication-deficient adenovirus vectors can be generated by replacing the *E1* gene — which is essential for viral replication — with the gene of interest (for example, that for factor IX) and an enhancer–promoter element. The recombinant vectors are then replicated in cells that express the products of the *E1* gene, and they can be generated in very high concentrations ( $>10^{11}$ – $10^{12}$  adenovirus particles per ml)<sup>15</sup>.

Cells infected with recombinant adenovirus can express the therapeutic gene but, because essential genes for viral replication are deleted, the vector should not replicate. These vectors can infect cells *in vivo*, causing them to express very high levels of the transgene. Unfortunately, this expression lasts for only a short time (5–10 days post-infection). In contrast to the retroviral vectors, long-term expression can be achieved if the recombinant adenoviral vectors are introduced into nude mice, or into mice that are given both the adenoviral vector and immunosuppressing agents<sup>16</sup>. This indicates that the immune system is behind the short-term expression that is usually obtained from adenoviral vectors.

The immune reaction is potent, eliciting both the cell-killing ‘cellular’ response and the antibody-producing ‘humoral’ response. In the cellular response, virally infected cells are killed by cytotoxic T lymphocytes<sup>16,17</sup>. The humoral response results in the generation of antibodies to adenoviral proteins, and it will prevent any subsequent infection if the animal is given a second injection of the recombinant adenovirus. Unfortunately for gene therapy, most of the human population will probably have antibodies to adenovirus from previous infection with the naturally occurring virus.

It is possible that the target cell contains factors that might trigger the synthesis of adenoviral proteins, leading to an immune response. To try to get around this problem, second-generation adenoviral vectors were developed, in which additional genes that are implicated in viral replication were deleted. These vectors showed longer-term expression, but a decline after 20–40 days was still apparent<sup>18</sup>. This idea has now been taken fur-

## What makes an ideal vector?

All of the current methods of gene delivery — whether viral or non-viral — have some limitation. So, the choice of vector will often be dictated by the need. If expression of the gene is required for only a short time (for example, expression of a toxic gene-product in cancer cells), then the adenoviral vectors are ideal. But if sustained expression is needed (such as for most genetic diseases), then an integrating vector

without attendant immunological problems is more desirable. An ideal vector may have to borrow properties from both viral and synthetic systems, and it should have:

- High concentration ( $>10^8$  viral particles per ml), allowing many cells to be infected;
- Convenience and reproducibility of production;
- Ability to integrate in a site-specific location in the host chromosome, or

to be successfully maintained as a stable episome;

- A transcriptional unit that can respond to manipulation of its regulatory elements;
- Ability to target the desired type of cell;
- No components that elicit an immune response.

Although no such vector is currently available, all of these properties exist, individually, in disparate delivery systems.

ther with the generation of ‘gut-less’ vectors — all of the viral genes are deleted, leaving only the elements that define the beginning and the end of the genome, and the viral packaging sequence. The transgenes carried by these viruses were expressed for 84 days<sup>19</sup>.

There are considerable immunological problems to be overcome before adenoviral vectors can be used to deliver genes and produce sustained expression. The incoming adenoviral proteins that package DNA can be transported to the cytoplasm where they are processed and presented on the cell surface, tagging the cell as infected for destruction by cytotoxic T cells. So adenoviral vectors are extremely useful if expression of the transgene is required for short periods of time. One promising approach is to deliver large numbers of adenoviral vectors containing genes for enzymes that can activate cell killing, or immunomodulatory genes, to cancer cells. In this case, the cellular immune response against the viral proteins will augment tumour killing. Finally, although immunosuppressive drugs can extend the duration of expression, our goal should be to manipulate the vector and not the patient.

### Adeno-associated viral vectors

A relative newcomer to the field, adeno-associated virus (AAV) is a simple, non-pathogenic, single-stranded DNA virus. Its two genes (*cap* and *rep*) are sandwiched between inverted terminal repeats that define the beginning and the end of the virus, and contain the packaging sequence<sup>20</sup>. The *cap* gene encodes viral capsid (coat) proteins, and the *rep* gene product is involved in viral replication and integration. AAV needs additional genes to replicate, and these are provided by a helper virus (usually adenovirus or herpes simplex virus).

The virus can infect a variety of cell types, and — in the presence of the *rep* gene product — the viral DNA can integrate preferen-

tially<sup>20</sup> into human chromosome 19. To produce an AAV vector, the *rep* and *cap* genes are replaced with a transgene. Up to  $10^{11}$ – $10^{12}$  viral particles can be produced per ml, but only one in 100–1,000 particles is infectious. Moreover, preparation of the vector is laborious and, due to the toxic nature of the *rep* gene product and some of the adenoviral helper proteins, we currently have no packaging cells in which all of the proteins can be stably provided. Vector preparations must also be carefully separated from any contaminating adenovirus, and AAV vectors can accommodate only 3.5–4.0 kilobases of foreign DNA — this will exclude larger genes. Finally, we need more information about the immunogenicity of the viral proteins, especially given that 80% of the adult population have circulating antibodies to AAV. These considerations notwithstanding, AAV vectors containing human factor IX complementary DNA have been used to infect liver and muscle cells in immunocompetent mice. The mice produced therapeutic amounts of factor IX protein in their blood for over six months<sup>21,22</sup>, confirming the promise of AAV as an *in vivo* gene-therapy vector.

### Other vectors

Among the other viruses being considered and developed, is herpes simplex virus, which infects cells of the nervous system<sup>23</sup>. The virus contains more than 80 genes, one of which (*IE3*) can be replaced to create the vector. Around  $10^8$ – $10^9$  viral particles are produced per ml, but the residual proteins are toxic to the target cell. Additional genes can be deleted, allowing more than one transgene to be included. But if essentially all of the viral proteins are deleted (gut-less vectors), only around  $10^6$  viral particles are produced per ml. And, again, many people have an immunity to components of herpes simplex virus, having already been infected at some time.

Vaccinia-virus-based vectors have also

been explored, largely for generating vaccines<sup>24</sup>. The Sindbis and Semliki Forest virus is being exploited as a possible cytoplasmic vector<sup>25</sup> which does not integrate into the nucleus. Although most of these systems produce the foreign protein only transiently, they add diversity to the available systems of gene transfer (Table 2).

**Clinical trials**

Over half of the 200 clinical trials that have been launched in the United States involve therapeutic approaches to cancer. Nearly 30 of them involve correction of monogenic diseases (Table 1) such as cystic fibrosis,  $\alpha_1$ -antitrypsin deficiency and severe combined immunodeficiency (SCID). Most of the trials are phase I (safety) studies and, by and large, the existing delivery systems have no major toxicity problems. Moreover, lessons can be learned from previous clinical trials<sup>26,27</sup>. For example, seven years ago two patients were enrolled in a trial to correct deficiencies in adenosine deaminase (ADA, which leads to severe immunodeficiency). One of the patients improved, and makes 25% of normal ADA in her T cells, five years after the last infusion of infected T cells (although she is still treated with PEG-ADA; bovine adenosine deaminase mixed with polyethylene glycol). But in the other patient, the infected T cells could not produce enough of the deficient enzyme.

The efficacy of gene therapy cannot be evaluated until patients are completely taken off alternative treatments (in the above example, PEG-ADA). In another trial<sup>28</sup>, weaning a patient away from PEG-ADA reduced the ability of the T cells to respond *in vitro* to a challenge by pathogens. Clearly, in these cases the retroviral vectors were not optimal, and the number of infected blood-progenitor cells was extremely low. However, these trials did help to establish the technology for generating clinical-grade recombinant retroviral particles, the

procedures for infection and transplantation, and the protocols for monitoring patients and analysing data. The disappointing outcome probably lies in the inefficient gene-delivery system. We need a system in which the vector — containing the ADA gene — is efficiently delivered to progenitor cells, leading to sustained expression of high levels of the ADA protein. But, encouragingly, despite being repeatedly injected with highly concentrated recombinant viruses, the patients have suffered no untoward effects to date.

**Future prospects**

We now need a renewed emphasis on the basic science behind gene therapy — particularly the three intertwined fields of vectors, immunology and cell biology.

All of the available viral vectors arose from understanding the basic biology of the structure and replication of viruses. Clearly, existing vectors need to be streamlined further (see box on page 241), and vectors that target specific types of cell are being developed. The use of antibody fragments, ligands to cell-specific receptors, or chemical modifications to the vector need to be explored systematically. And advances such as the report — published only last week<sup>29</sup> — of the three-dimensional structure of the Env protein from mouse leukaemia virus (a commonly used vector), will facilitate the design of targeted vectors. A better understanding of gene transcription will allow us to design regulatory elements that permit promoter activity to be modulated, and development of tissue-specific enhancer-promoter elements should be vigorously pursued. Finally, we need to begin merging some of the qualities of viral vectors with non-viral vectors, to generate a safe and efficient gene-delivery system.

With respect to immunology, viruses still have many secrets to be unravelled. Viral systems that have evolved to escape immune surveillance can be incorporated into viral

vectors. Some of these are being characterized; for example, the adenoviral E3 protein, the herpes simplex ICP47 protein and the cytomegalovirus US11 protein<sup>30</sup>. Systems from other pathogens may also be borrowed and incorporated into vectors. In some cases, the correcting protein will be sensed as foreign, eliciting an immune response. Animal models should help us to understand this and, where necessary, to develop strategies for tolerance.

Cell biology is involved because, in many cases, the goal of gene therapy is to correct differentiated cells, such as epithelial cells in cystic fibrosis and lymphoid cells in ADA deficiency. However, because these cells are continuously replaced there has to be either continued therapy or an attempt to target the stem cells. We first need to develop further the technologies for identifying and isolating these cells, to understand their regulation, and to target infection to them *in vivo*.

So how far have we come since clinical trials began? The promises are still great, and the problems have been identified (and they are surmountable). But what of the prospects? Our view is that, in the not too distant future, gene therapy will become as routine a practice as heart transplants are today. □

Inder M. Verma and Nikunj Somia are in the Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.

- Crystal, R. G. *Science* **270**, 404–410 (1995).
- Scriver, C. R. S., Beaudet, A. L., Sly, W. S. & Valle, D. V. *The Metabolic Basis of Inherited Disease* (McGraw-Hill, New York, 1989).
- Dai, Y., Roman, M., Naviaux, R. K. & Verma, I. M. *Proc. Natl Acad. Sci. USA* **89**, 10892–10895 (1992).
- Kay, M. A. *et al. Science* **262**, 117–119 (1993).
- St Louis, D. & Verma, I. M. *Proc. Natl Acad. Sci. USA* **85**, 3150–3154 (1988).
- Felgner, P. L. *Sci. Am.* **276**, 102–106 (1997).
- Verma, I. M. *Sci. Am.* **263**, 68–72 (1990).
- Miller, D. G., Adam, M. A. & Miller, A. D. *Mol. Cell. Biol.* **10**, 4239–4242 (1990).
- Palmer, T. D., Rosman, G. J., Osborne, W. R. & Miller, A. D. *Proc. Natl Acad. Sci. USA* **88**, 1330–1334 (1991).
- Lewis, P., Hensel, M. & Emerman, M. *EMBO J.* **11**, 3053–3058 (1992).
- Field, B. N., Knipe, D. M. & Howley, P. M. (eds) *Virology* (Lippincott-Raven, Philadelphia, PA, 1996).
- Naldini, L. *et al. Science* **272**, 263–267 (1996).
- Miyoshi, H., Takahashi, M., Gage, F. H. & Verma, I. M. *Proc. Natl Acad. Sci. USA* **94**, 10319–10323 (1997).
- Blömer, U. *et al. J. Virol.* **71**, 6641–6649 (1997).
- Yeh, P. & Perricaudet, M. *FASEB J.* **11**, 615–623 (1997).
- Dai, Y. *et al. Proc. Natl Acad. Sci. USA* **92**, 1401–1405 (1995).
- Yang, Y., Ertl, H. C. & Wilson, J. M. *Immunity* **1**, 433–442 (1994).
- Engelhardt, J. F., Ye, X., Doranz, B. & Wilson, J. M. *Proc. Natl Acad. Sci. USA* **91**, 6196–6200 (1994).
- Chen, H. H. *et al. Proc. Natl Acad. Sci. USA* **94**, 1645–1650 (1997).
- Muzyczka, N. *Curr. Top. Microbiol. Immunol.* **158**, 97–127 (1992).
- Snyder, R. O. *et al. Nature Genet.* **16**, 270–276 (1997).
- Herzog, R. W. *et al. Proc. Natl Acad. Sci. USA* **94**, 5804–5809 (1997).
- Fink, D. J., DeLuca, N. A., Goins, W. F. & Glorioso, J. C. *Annu. Rev. Neurosci.* **19**, 265–287 (1996).
- Moss, B. *Proc. Natl Acad. Sci. USA* **93**, 11341–11348 (1996).
- Berglund, P. *et al. Biotechnology (NY)* **11**, 916–920 (1993).
- Blaese, R. M. *et al. Science* **270**, 475–480 (1995).
- Bordignon, C. *et al. Science* **270**, 470–475 (1995).
- Kohn, D. B. *et al. Nature Med.* **1**, 1017–1023 (1995).
- Fass, D. *et al. Science* **277**, 1662–1665 (1997).
- Wiertz, E. J. *et al. Cell* **84**, 769–779 (1996).

Table 2 **Comparison of properties of various vector systems**

Features	Retroviral	Lentiviral	Adenoviral	AAV	Naked/ lipid-DNA
Maximum insert size	7–7.5 kb	7–7.5 kb	~30 kb	3.5–4.0 kb	Unlimited size
Concentrations (viral particles per ml)	>10 <sup>8</sup>	>10 <sup>8</sup>	>10 <sup>11</sup>	>10 <sup>12</sup>	No limitation
Route of gene delivery	<i>Ex vivo</i>	<i>Ex/In vivo</i>	<i>Ex/In vivo</i>	<i>Ex/In vivo</i>	<i>Ex/In vivo</i>
Integration	Yes	Yes	No	Yes/No	Very poor
Duration of expression <i>in vivo</i>	Short	Long	Short	Long	Short
Stability	Good	Not tested	Good	Good	Very good
Ease of preparation (scale up)	Pilot scale up, up to 20–50 l	Not known	Easy to scale up	Difficult to purify, difficult to scale up	Easy to scale up
Immunological problems	Few	Few	Extensive	Not known	None
Pre-existing host immunity	Unlikely	Unlikely, except maybe AIDS patients	Yes	Yes	No
Safety problems	Insertional mutagenesis?	Insertional mutagenesis?	Inflammatory response, toxicity	Inflammatory response, toxicity	None